Cancer Chemoprevention

Promising Cancer Chemopreventive Agents

  • Gary J. Kelloff
  • Ernest T. Hawk
  • Caroline C. Sigman

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Antimutagens

    1. Front Matter
      Pages 1-1
    2. Thomas W. Kensler, Paul Talalay
      Pages 3-20
    3. Stephen S. Hecht
      Pages 21-35
    4. Silvio De Flora, Alberto Izzotti, Adriana Albini, Francesco D’Agostini, Maria Bagnasco, Roumen Balansky
      Pages 37-67
    5. John DiGiovanni, Heather E. Kleiner
      Pages 69-84
  3. Antiinflammatories

    1. Front Matter
      Pages 85-85
    2. Gary B. Gordon, Gary J. Kelloff, Caroline C. C. Sigman
      Pages 87-105
    3. Susan M. Fischer, Russell D. Klein
      Pages 115-131
    4. Lorne J. Hofseth, Tomohiro Sawa, S. Perwez Hussain, Curtis C. Harris
      Pages 133-151
    5. Timothy S. Wiedmann, Lee W. Wattenberg
      Pages 153-167
    6. Bandaru S. Reddy, Chinthalapally V. Rao
      Pages 169-175
    7. Robert L. Keith, York E. Miller, Paul A. Bunn Jr., Patrick Nana-Sinkam, Raphael A. Nemenoff, Mark W. Geraci
      Pages 177-191
  4. Nuclear Receptor Superfamily

    1. Front Matter
      Pages 193-193
    2. Julia A. Lawrence, Kapil Dhingra
      Pages 195-208
    3. Antiandrogens

      1. Jennifer E. Drisko, Siu-Long Yao
        Pages 211-218
      2. Mark S. Chapman, William Y. Chang, Andres Negro-Vilar, Jeffrey N. Miner
        Pages 219-228
    4. Antiestrogens

About this book


Much progress has been made in discovering and developing agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. In Cancer Chemoprevention, Volume 1: Promising Cancer Chemopreventive Agents, leading researchers in the discovery and development of chemopreventives comprehensively survey all aspects of these emerging therapeutics. For each agent, the authors review the relevant mechanisms of action, the criteria for populations benefiting from intervention, the safety and pharmacodynamics, clinical study design emphasizing the use of precancers, and early associated cellular and molecular biomarkers of carcinogenesis. The pharmacologic and/or mechanistic classes discussed range from antimutagens, antiinflammatories, and the nuclear receptor superfamily, to signal transduction modulators, antioxidants, vitamins, and minerals. The classes vary widely in terms of their stages of development as chemopreventives and include both extensively studied groups and those with recently identified potential based on such mechanistic data as protein kinase inhibition. Attention is also devoted to nutriceuticals (food-derived agents) because of their high promise for prevention in healthy populations. The overall focus is on molecular targets and mechanisms. A second volume, Strategies for Cancer Chemoprevention, describes the exciting methodologies that are accelerating progress in this field and discusses the state of clinical development of chemoprevention in the various human cancer target organs.
Up-to-date and highly practical, Cancer Chemoprevention, Volumes 1 & 2, offer oncologists, pharmacologists, medicinal chemists, and toxicologists a comprehensive reference survey on the identification of promising cancer chemopreventive agents that will help stimulate further research and the development of novel approvable drugs.


Antigen Drogen cancer cancer prevention carcinogenesis cell chemotherapy metabolism mutagen oncogene pharmacodynamics prevention prostate cancer research tumor

Editors and affiliations

  • Gary J. Kelloff
    • 1
  • Ernest T. Hawk
    • 1
  • Caroline C. Sigman
    • 2
  1. 1.National Institutes of HealthRockvilleUSA
  2. 2.CCS AssociatesMountain ViewUSA

Bibliographic information

  • DOI
  • Copyright Information Humana Press 2004
  • Publisher Name Humana Press, Totowa, NJ
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-61737-342-8
  • Online ISBN 978-1-59259-767-3
  • About this book